# HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

> **NCT04496999** · PHASE1 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 2 (actual)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** HDM201
- **DRUG:** Midostaurin

## Key facts

- **NCT ID:** NCT04496999
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-13
- **Primary completion:** 2022-09-09
- **Final completion:** 2022-09-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Insufficient recruitment
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04496999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04496999, "HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04496999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*